There is limited prognostic information to identify breast cancer patients who are at risk for late recurrences after adjuvant or neoadjuvant systemic therapy (AST). We evaluated the residual risk of recurrence and prognostic factors of 2838 patients with stage I -III breast cancer who were treated with AST between January 1, 1985, and November 1, 2001, and remained disease free for 5 years. Residual recurrencefree survival was estimated from the landmark of 5 years after AST to date of first recurrence or last follow-up using the Kaplan -Meier method. The log-rank test (two-sided) was used to compare groups. Residual recurrence-free survival rates at 5 and 10 years were 89% and 80%, respectively, and 216 patients developed a recurrence event. The 5-year residual risks of recurrence for patients with stage I, II, and III cancers were 7% (95% confidence interval [CI] = 3% to 15%), 11% (95% CI = 9% to 13%), and 13% (95% CI = 10% to 17%), respectively ( P = .02). In multivariable analysis, stage, grade, hormone receptor status, and endocrine therapy were associated with late recurrences. Breast cancer patients have a substantial residual risk of recurrence, and selected tumor characteristics are associated with late recurrences.
BRIEF COMMUNICATIONS
chemotherapy and/or endocrine therapy; and 4) were alive and remained disease free 5 years from the start of AST. A total of 3064 patients who met study criteria were identifi ed from the PDMS and BCMS databases. Two hundred and twenty-six patients were excluded because they were male (n = 9), had incomplete staging information or stage IV disease (n = 53), had no information available regarding date of surgery (n = 14), did not receive defi nitive surgery for the primary breast cancer (n = 21), or died or were found to have a breast cancer recurrence within 5 years from start of AST (n = 129). The fi nal study population consisted of 2838 patients.
Follow-up information was obtained by medical record review and matched with the MDACC Tumor Registry, which annually mails letters to patients who are known to be alive to determine their clinical status. The study was approved by the MDACC Institutional Review Board, which granted a waiver of in formed consent for this study.
The primary study endpoint was time to breast cancer recurrence, which was defi ned as local lymph node or breast recurrence, metastasis to other sites, or second primary breast cancer. Residual recurrence-free survival was calculated from the landmark of 5 years from the start of AST to the date of fi rst disease recurrence or last follow-up. We used this landmark because the majority of women with hormone receptor -positive tumors completed 5 years of adjuvant endocrine therapy, and we were interested in evaluating the residual risk of recurrence after the completion of AST. Patients who died Adjuvant or neoadjuvant systemic therapy (AST) for breast cancer improves survival, yet a substantial number of women remain at risk for late recurrences ( 1 , 2 ) . Identifying patients who are at risk for late recurrences has clinical relevance because extended adjuvant endocrine therapy with letrozole improves the disease-free survival of postmenopausal women with estrogen receptor (ER) -or progesterone receptor (PR) -positive tumors after 5 years of tamoxifen therapy ( 3 ). Extended adjuvant endocrine therapy is recommended for postmenopausal women with endocrine responsive breast cancers ( 4 -6 ); however, limitations in the ability to predict the magnitude of the risk of late recurrence may contribute to some patients receiving unnecessary extended adjuvant endocrine therapy and others receiving no treatment. Few studies have evaluated the magnitude of the risk of late recurrence among patients who remain disease free 5 years after AST, which is a clinically relevant estimate for weighing the risks and benefi ts of extended adjuvant endocrine therapy ( 7 ). We therefore identifi ed a cohort of patients with earlystage breast cancer and determined the magnitude of the residual risk of breast cancer recurrence after 5 years from the start of AST and the prognostic signifi cance of patient and tumor characteristics.
Patients included in this study were 
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without a recurrence or who were not known to have a recurrence at the date of last contact were censored. Hazard ratios (HRs) and 95% confi dence intervals (CIs) were estimated using Cox proportional hazards regression models. The P values in the univariate analysis were based on the log-rank test, and the 5-and 10-year estimates and 95% confi dence intervals were based on the Kaplan -Meier estimates, with standard error based on Greenwood estimator. Recurrence-free survival was considered in a multivariable setting with Cox proportional hazards models. Age at diagnosis ( ≤ 35, 36 -59, or ≥ 60 years), year of start of AST (before 1992 or 1992 or later), hormone receptor status (ER positive and/ or PR positive, or ER negative and PR negative), chemotherapy (anthracycline, anthracycline and taxane, other, or none), endocrine therapy (tamoxifen, aromatase inhibitor, tamoxifen and aromatase inhibitors, other, or none), stage (I, II, or III), surgery type (breast conserving or mastectomy), radiation (yes or no), and grade (1, 2, or 3) were considered for inclusion in the multivariable model and were evaluated by both the Wald test and the likelihood ratio test. The proportional hazards assumption was tested for the variables included in the multivariable model, and the global P value was .20, indicating that the assumption was not violated for the fi tted multivariable Cox model ( 8 ) . The Kaplan -Meier product limit method ( 9 ) was also used to estimate residual recurrence-free survival, and the log-rank test was used to compare groups. Tumors that were ER or PR positive were defi ned as hormone receptor positive. All statistical tests were two-sided, and P values less than .05 were considered statistically signifi cant. We used SAS version 9.1 (SAS Institute, Cary, NC) to perform the analyses.
The majority of patients (52%) were postmenopausal; 9% were black, 12% Hispanic, 73% white, and 3% of other ethnicities ( Table 1 ). The median follow-up time for the cohort after 5 years from the start of AST was 28 months (range = 0.02 to 185.6 months). The 5-and 10-year residual recurrence-free survival rates (10 and 15 years from start of AST) were 89% and 80%, respectively, and 216 patients developed a recurrence event. The median time from surgery to start of adjuvant therapy was 35 days (range = 1 to 955 days) and that from the start of neoadjuvant therapy to surgery was 107 days (range = 29 to 608 days). Adjuvant tamoxifen therapy was not routinely prescribed to premenopausal women until 1998. Patients with stages I, II, and III disease had a residual 5-year risk of recurrence of 7% (95% CI = 3% to 15%), 11% (95% CI = 9% to 13%), and 13% (95% CI = 10% to 17%), respectively. The small number of stage I patients (n = 3) who were at risk for an event at 15 years from the start of AST makes the 10-year residual risk estimate unreliable ( Figure 1 ) . The residual risk of recurrence was statistically signifi cantly higher for patients with hormone receptor -positive tumors than for those with hormone receptor -negative tumors in a stratifi ed analysis by endocrine therapy ( P < .001; Table 1 ). Patients with hormone receptor -positive tumors had a higher residual risk of recurrence than patients with hormone receptornegative tumors regardless of menopausal status (data not shown).
The multivariable model included hormone receptor status, endocrine therapy, stage, surgery type, and grade. Factors that were associated with increased risk of recurrence 5 years after the start of AST were stage III vs stage I disease (HR = 2.49, 95% CI = 1.33 to 4.66; P = .004), stage II vs stage I disease (HR = 2.13, 95% CI = 1.21 to 3.75; P = .009), and hormone receptorpositive tumors not treated with endocrine therapy vs hormone receptor -negative tumors (HR = 1.84, 95% CI = 1.19 to 2.87; P = .006). Patients with hormone receptorpositive tumors who were treated with endocrine therapy had an approximately 50% higher residual risk of recurrence than patients with hormone receptor -negative tumors, but this difference was not statistically signifi cant (HR = 1.49, 95% CI = 0.95 to 2.34; P = .08). Patients with grade 3 tumors had a lower residual risk of recurrence than patients with grade 1 tumors (HR = 0.47, 95% CI = 0.23 to 0.95; P = .036). We also evaluated the clinical characteristics that were associated with residual risk of recurrence among patients with hormone receptor -positive tumors who received chemotherapy and endocrine therapy or endocrine therapy alone. Among these patients, the residual risk of recurrence was infl uenced by the same factors as observed in the overall population. There was also no association in the residual risk of recurrence between hormone receptor -positive patients who were treated with chemotherapy plus endocrine therapy vs those treated with endocrine therapy alone (data not shown).
These fi ndings agree with previous studies showing a higher annual risk of recurrence among patients with larger tumors and lymph node involvement who were treated with AST and followed for 5 -15 years ( 10 , 11 ) . In this study, low-grade and positive hormone receptor status, which are associated with favorable shortterm prognosis ( 12 , 13 ) , were associated with a higher residual risk of recurrence. Studies ( 14 , 15 ) have demonstrated that the survival advantage of hormone receptorpositive tumors is time dependent, because at longer follow-up, patients with hormone receptor -negative tumors have a survival
CONTEXT AND CAVEATS

Prior knowledge
Adjuvant and neoadjuvant systemic therapy (AST) improves the survival of breast cancer patients, but there is still a risk that the disease will recur years later.
Study design
Disease recurrence among breast cancer patients who were disease free 5 years after AST (the landmark) was estimated 5 and 10 years after landmark. Multivariable analysis was used to identify factors associated with recurrence.
Contributions
Rates of recurrence-free survival at 5 years and 10 years after landmark were 89% and 80%, respectively. The risk of recurrence 5 years after therapy increased with tumor stage (stage 1: 7%, stage II: 11%, and stage 3: 13%) and was also associated with tumor grade, hormone receptor status, and endocrine therapy.
Implications
Breast cancer patients who undergo AST are at risk of late recurrences, and this risk is associated with certain characteristics of the original tumor. Limitations HER2/neu status was not included in the analysis because the data were not available; aromatase inhibitor treatment was not included because too few women received it. rate that is similar to or more favorable than that of patients with hormone receptorpositive tumors. In the current study, among the patients with hormone receptorpositive breast cancer, higher stage and lower grade were also associated with residual risk of recurrence. The receipt of chemotherapy in addition to endocrine therapy did not infl uence the residual risk of recurrence; however, these results should be considered with caution because the sample consisted of a mixed population of hormone receptor -positive tumors, some of whom (n = 44) were enrolled in a randomized study of adjuvant endocrine therapy alone vs chemotherapy alone ( 16 ) . The higher residual risk of recurrence associated with hormone receptor -positive tumors has important clinical implications. There are no proven therapeutic options for extended adjuvant endocrine therapy for premenopausal women who have completed 5 years of tamoxifen therapy ( 17 -20 ) . The magnitudes of the residual risk of recurrence for pre-and postmenopausal patients were within the range (8% -20%) considered appropriate to recommend AST at the time of diagnosis, indicating a need for the continued development of risk reduction strategies for these survivors.
From the Editors
A limitation of our study is that we were unable to assess the prognostic signifi cance of Her2/neu expression because these data were not available. In addition, few patients received adjuvant therapy that included aromatase inhibitors before 2001, and therefore, the residual risk of recurrence associated with this treatment was not assessed. Extended adjuvant endocrine therapy after aromatase inhibitor treatment has not been evaluated in randomized trials, and the benefi ts are undefi ned. The strengths of the study are the large sample size of ethnically diverse patients who were treated with AST with long-term follow-up.
In conclusion, this study demonstrates that patients with early-stage breast cancer who are disease free at 5 years after AST have a substantially increased residual risk of recurrence. Extended adjuvant endocrine therapy is currently available only for postmenopausal patients with hormone receptor -positive disease, and these patients should be considered for treatment after careful evaluation of the risks and benefi ts. More research is needed to identify host and tumor characteristics that are associated with late breast cancer recurrences to individualize initial AST and extended adjuvant endocrine therapy.
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